Economic Evaluations of Immunoprophylaxis in Infants at High Risk for Respiratory Syncytial Virus
Shedding Light or Creating Confusion?
Arch Pediatr Adolesc Med. 2002;156:1180-1181.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
GREAT ADVANCES in pediatrics have arisen from the discovery of new drugs designed to treat diseases that may cause death or severe morbidity in children. These discoveries most often arise from basic research and are brought to market by pharmaceutical companies at an estimated cost of $500 million per drug.1 No one can dispute that much benefit to patients has emerged from these developments.
Increasing emphasis is being placed on the need for decisions in health care to be evidence based. With the recognition that health care resources are limited, it has become equally important for new interventions to undergo economic evaluations. Without such examinations of the efficiency of new interventions, the costs of health care will escalate at an ever-faster rate. In many countries, costs for pharmaceutical agents are becoming the fastest-growing component in their health care budgets.
Bronchiolitis is a disease that has frustrated pediatricians for many years . . . [Full Text of this Article]
|
